441O A Phase I Clinical Trial on the Intracranial Administration of Autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ Myeloid Dendritic Cells (mydc) in Combination with Ipilimumab (IPI) and Nivolumab (NIVO) in Patients with Recurrent High-Grade Glioma (Rhgg)